The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 11, 2017
Filed:
Apr. 22, 2015
Ludwig Institute for Cancer Research Ltd., New York, NY (US);
Sloan Kettering Cancer Institute, New York, NY (US);
Institute of Molecular Biology and Genetics National Academy of Science of Ukraine, Kiev, UA;
Gerd Ritter, New York, NY (US);
Beatrice Yin, New York, NY (US);
Anne Murray, New York, NY (US);
George Mark, New York, NY (US);
Lloyd J. Old, New York, NY (US);
Kenneth Lloyd, New York, NY (US);
Serhiy Souchelnytskiy, Stockholm, SE;
Ivan Gout, London, GB;
Valeriy Filonenko, Kiev, UA;
Ramziya Kiyamova, Kiev, UA;
Ludwig Institute for Cancer Reserach Ltd., New York, NY (US);
Sloan Kettering Cancer Institute, New York, NY (US);
Institute of Molecular Biology and Genetics National Academy of Science of Ukraine, Kiev, UA;
Abstract
The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.